High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis

Leukemia Research

Volumn 35, Issue 10, 2011, Pages 1330-1334

  Hasselbalch, Hans Carl ^a   Skov, Vibe ^b   Larsen, Thomas Stauffer ^b   Thomassen, Mads ^b   Riley, Caroline Hasselbalch ^a   Jensen, Morten K ^a   Bjerrum, Ole Weis ^a   Kruse, Torben A ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Angiogenesis; Carcinoembryonic antigen related cell adhesion molecule (CEACAM) 6 and 8; CD34+ cells; Cell adhesion; Inflammation; Primary myelofibrosis; Whole blood gene expression profiling

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CD34 ANTIGEN; MOLECULAR MARKER;

ADULT; AGED; ARTICLE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1 GENE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 19 GENE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 21 GENE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 3 GENE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 4 GENE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 5 GENE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6 GENE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 7 GENE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 8 GENE; CELL ADHESION; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; LEUKOCYTE ACTIVATION; MALE; MARKER GENE; MOLECULAR PATHOLOGY; MYELOID METAPLASIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSCRIPTION INITIATION; UPREGULATION;

AGED; ANTIGENS, CD; ANTIGENS, CD34; BIOLOGICAL MARKERS; BONE MARROW; CASE-CONTROL STUDIES; CELL ADHESION; CELL ADHESION MOLECULES; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; GPI-LINKED PROTEINS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHIL ACTIVATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRIMARY MYELOFIBROSIS; T-LYMPHOCYTES;

EID: 80052095665     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.03.013     Document Type: Article

References (44)

1. Benchimol S., Fuks A., Jothy S., Beauchemin N., Shirota K., Stanners C.P. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989, 57:327-334.
2. Wagener C., Ergun S. Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1. Exp Cell Res 2000, 261:19-24.
3. Kuespert K., Pils S., Hauck C.R. CEACAMs: their role in physiology and pathophysiology. Curr Opin Cell Biol 2006, 18(5):565-571.
4. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000, 342(17):1255-1265.
5. Barosi G., Viarengo G., Pecci A., Rosti V., Piaggio G., Marchetti M., et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001, 98(12):3249-3255.
6. Xu M., Bruno E., Chao J., Huang S., Finazzi G., Fruchtman S.M., et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood 2005, 105(11):4805-4815.
7. Lataillade J.J., Pierre-Louis O., Hasselbalch H.C., Uzan G., Jasmin C., Martyré M.C., et al. French INSERM and the European EUMNET Networks on Myelofibrosis. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 2008, 112(8):3026-3035.
8. Hasselbalch H.C. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?. Leuk Res 2009, 33(1):11-18.
9. Dupriez B., Morel P., Demory J.L., Lai J.L., Simon M., Plantier I., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996, 88:1013-1018.
10. Cervantes F., Pereira A., Esteve J., Rafel M., Cobo F., Rozman C., et al. Identification of "short-lived" and "long-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997, 97:635-640.
11. Tefferi A., Huang J., Schwager S., Li C.Y., Wu W., Pardani A., et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis base on 334 patients from a single institution. Cancer 2007, 109:2083-2088.
12. Hasselbalch H.C. Idiopathic myelofibrosis. A review. Eur J Haematol 1990, 45:65-72.
13. Ihaka R., Gentleman R. R: a language for data analysis and graphics. J Comp Graph Stat 1996, 5:299-314.
14. Irizarry R.A., Hobbs B., Collin F., Beazer-Barclay Y.D., Antonellis K.J., Scherf U., et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
15. Smyth G.K. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:1-25. [article 3].
16. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995, 57:289-300.
17. Stern N., Markel G., Arnon T.I., Gruda R., Wong H., Gray-Owen S.D., et al. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol 2005, 174:6692-6701.
18. Gray-Owen S.D., Blumberg R.S. CEACAM1: contact-dependent control of immunity. Nat Rev Immunol 2006, 6(6):433-446.
19. Häger M., Cowland J.B., Borregaard N. Neutrophil granules in health and disease. J Intern Med 2010, 268(1):25-34.
20. Nittka S., Gunther J., Ebisch C., Erbersdobler A., Neumaier M. The human tumour suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis. Oncogene 2004, 23:9306-9313.
21. Sienel W., Dango S., Woelfle U., Morresi-Hauf A., Wagener C., Brümmer J., et al. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res 2003, 9(6):2260-2266.
22. Duxbury M.S., Matros E., Clancy T., Bailey G., Doff M., Zinner M.J., et al. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann Surg 2005, 241(3):491-496.
23. Dango S., Sienel W., Schreiber M., Stremmel C., Kirschbaum A., Pantel K., et al. Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer. Lung Cancer 2008, 60(3):426-433.
24. Maraqa L., Cummings M., Peter M.B., Shaaban A.M., Horgan K., Hanby A.M., et al. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res 2008, 14(2):405-411.
25. Serra S., Asa S.L., Bamberger A.M., Wagener C., Chetty R. CEACAM1 expression in pancreatic endocrine tumors. Appl Immunohistochem Mol Morphol 2009, 17(4):286-293.
26. Strickland L.A., Ross J., Williams S., Ross S., Romero M., Spencer S., et al. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol 2009, 218(3):380-390.
27. Singer B.B., Scheffrahn I., Kammerer R., Suttorp N., Ergun S., Slevogt H. Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS One 2010, 5(1):e8747.
28. Messick C.A., Sanchez J., Dejulius K.L., Hammel J., Ishwaran H., Kalady M.F. CEACAM-7: a predictive marker for rectal cancer recurrence. Surgery 2010, 147(5):713-719.
29. Sugita K., Mori T., Yokota S., Kuroki M., O-Koyama T., Inukai T., et al. The Kor-SA3544 antigen predominantly expressed on the surface of Philadelphia chromosome-positive acute lymphoblastic leukemia cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed in cytoplasm of human leukemia cells. Leukemia 1999, 13:779-785.
30. Lasa A., Serrano E., Carricondo M., Carnicer M.J., Brunet S., Badell I., et al. High expression of CEACAM6 and CEACAM8 mRNA in acute lymphoblastic leukemias. Ann Hematol 2008, 87(3):205-211.
31. Ordonez C., Screaton R.A., Ilantzis C., Stanners C.P. Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res 2000, 60:3419-3424.
32. Duxbury M.S., Ito H., Zinner M.J., Ashley S.W., Whang E.E. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 2004, 23:465-473.
33. Martin M.J., Melnyk N., Pollard M., Bowden M., Leong H., Podor T.J., et al. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol 2006, 26:1754-1769.
34. Campi G., Crosti M., Consogno G., Facchinetti V., Conti-Fine B.M., Longhi R., et al. CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 2003, 63:8481-8486.
35. Silver R.T. Interferon in the treatment of the myeloproliferative disorders. Semin Hematol 1990, 27:6-14.
36. Bachleitner-Hofmann T., Gisslinger H. The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann Hematol 1999, 78(12):533-538.
37. Quintas-Cardama A., Kantarjian H.M., Luthra R., Estrov Z., Pierce S., et al. Pegylated interferon-alfa-2a therapy yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009, 27:5418-5424.
38. Kiladjian J.J., Cassinat B., Turlure P., Turlure P., Cambier N., Roussel M., et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 2006, 108:2037-2040.
39. Kiladjian J.J., Cassinat B., Chevret S., Turlure P., Cambier N., Roussel M., et al. Pegylated Interferon-alfa-2a induces complete haematological and molecular responses with low toxicity in polycythemia vera. Blood 2008, 112(8):3065-3072.
40. Kiladjian J.J., Chomienne C., Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008, 22(11):1990-1998.
41. Larsen T.S., Bjerrum O.W., Pallisgaard N., Andersen M.T., Møller M.B., Hasselbalch H.C. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Ann Hematol 2008, 87(10):847-850.
42. Larsen T.S., Møller M.B., de Stricker K., Nørgaard P., Samuelsson J., Marcher C., et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete haematological remission. Hematology 2009, 14(6):331-334.
43. Silver R.T., Vandris K. Recombinant interferon alpha(rIFN-alpha-2b) may retard progression of early myelofibrosis. Leukemia 2009, 23(7):1366-1369.
44. Ianotto J.C., Kiladjian J.J., Demory J.L., Roy L., Boyer F., Rey J., et al. PEG-IFN-2a therapy in patients with myelofibrosis. A study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol 2009, 146:218-230.